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Introduction 
The majority of ovarian cancer patients experience relapse of their disease despite initial complete or 
partial response to treatment. Strategies for treating recurrent ovarian cancer depend on platinum 
sensitivity; however, regardless of primary platinum sensitivity, most tumors eventually become platinum 
resistant[1]. Non-platinum containing regimens in this setting include the topoisomerase I-inhibitor 
topotecan. Inhibition of the nuclear enzyme, topoisomerase I, which is involved in replication, transcription, 
and repair of DNA, induces temporary DNA single-strand breaks, which potentially induces cell apoptosis, 
predominantly in heavily replicating cells such as tumor cells[2]. Response rates of topotecan monotherapy 
in platinum resistant or partially platinum sensitive recurrent ovarian cancer vary from 0-18%, whereas the 
response in platinum sensitive ovarian cancers is somewhat better, 12-33%[2–5].  
Pharmacological inhibition of another nuclear enzyme, poly-(adenosine-diphosphate-ribose) polymerase 
(PARP), was recently approved  (olaparib) by The European Medicines Agency (EMA) as monotherapy of 
platinum sensitive relapse of BRCA1/2 (breast cancer early onset) mutated (germline and somatic) 
epithelial ovarian cancer based on randomized phase II trials[6–9]. Promptly after this, the United States 
Food and Drug Administration (U.S. FDA) approved olaparib as monotherapy of recurrent germline 
BRCA1/2 mutated epithelial ovarian cancer in patients previously treated with three or more prior lines of 
chemotherapy [10,11]. PARP is essential to repair of single-strand DNA breaks by the base-excision repair 
mechanism, whereas the BRCA1/2 proteins are essential to DNA double-strand break repair by homologous 
recombination (HR). A number of other genes are involved in the HR pathway, and the BRCA gene may be 
inactivated by hypermethylation in addition to germline or somatic mutation. The BRCAness phenomenon 
describes an HR deficient tumor without a germline BRCA mutation. PARP inhibition in an HR dysfunctional 
cell induces selective cell kill termed synthetic lethality. PARP inhibition generates non-repaired DNA single-
strand breaks to accumulate as DNA double-strand breaks by subsequent replication. In an HR deficient 
cell, which relies on the error-prone mechanisms of non-homologous end joining (NHEJ) and single-strand-
annealing, this accumulation results in cell death [12,13].  
Originally, PARP inhibitors were proposed as chemotherapy sensitizers[14–16]. Inhibition of the PARP 
enzyme renders tumor cells especially sensitive to cytostatic agents by blocking the base excision repair of 
DNA single-strand breaks. This results, in part, in slower repair of DNA damage, a lower threshold for 
apoptosis and thus increased sensitivity to cytostatic drugs[17,18]. Previous studies have shown that PARPi 
is a potent chemotherapy sensitizer, regardless of BRCA function[19]. Studies combining PARPi with 
chemotherapy generally report enhanced hematological toxicity [20,21]; however successful combination 
regimens have led to further phase II [7] and ongoing phase III trials, e.g. ClinicalTrials.gov NCT02470585.   
We hypothesized that co-administration of the PARP inhibitor veliparib with the topoisomerase-I inhibitor 
topotecan would enhance the anti-tumor effect in patients without BRCA1/2 germline mutations or 
unknown BRCA1/2 status.   
 
Material and methods 
Study design 
This prospective, nonrandomized phase I/II study included women with advanced primary epithelial 
ovarian, fallopian tube or peritoneal cancer without germline BRCA1/2 mutations or with unknown BRCA 
mutation status. Patients were enrolled and treated at the Department of Oncology, Vejle Hospital, 
Denmark. Study subjects received an initial dose of oral veliparib, 30 mg twice a day, on days 1-3, 8-10 and 
15-17, and intravenous topotecan (3 mg/m2) on days 2, 9, and 16. Treatment cycles of 28 days were 
repeated until progression, intolerable toxicity, patient wish for withdrawal, long term treatment delays (>4 
weeks), or lack of study compliance. Dose escalation of veliparib took place in cohorts of 3 to 6 patients in a 
classic phase I, 3+3 design with an escalation to the next dose level if no dose limiting toxicities were seen; 
choice of dose, administration and dose escalation design was in continuation with 2 ongoing phase I/II 
studies (ClinicalTrials.gov, NCT00892736; NCT01012817). The study was commenced in January 2013 and 
the last patient included in October 2014. The last study treatment was administered in January 2015.  
Patients 
Eligibility criteria were histologically confirmed diagnosis of epithelial primary ovarian, fallopian tube or 
peritoneal cancer, stage I-IV, minimum age of 18 years, written informed consent, ECOG performance 
status 0-2, platinum resistant or partially platinum sensitive disease, adequate liver, bone marrow and renal 
function and coagulation parameters (7 days prior to inclusion), tumor tissue available for BRCAness 
analysis (somatic BRCA1/2 and other HR-gene mutations), a washout period of 28 days of prior anticancer 
treatment, verified disease progression by RECIST criteria and/or by GCIG CA-125 criteria after previous first 
line chemotherapy or progression after further regimens of chemotherapy, and measurable disease by 
RECIST 1.1 or evaluable by GCIG CA-125 criteria[22,23].  
Key exclusion criteria were prior treatment with a PARP inhibitor, known BRCA1/2 germline mutations, 
previous topotecan treatment terminated or dose reduced due to toxicity, other previous or present 
malignancy, CNS metastasis, and uncontrolled chronic, medical or psychiatric conditions.  
The study was conducted in accordance with the Helsinki II Declaration and the International Conference 
on Harmonization Good Clinical Practice (ICH-GCP) guidelines and the applicable official legislation and 
approved by The Regional Committee on Health Research Ethics for Southern Denmark (S-20120078), The 
Danish Health and Medicines Authority and the Data Protection Agency. ClinicalTrials.gov, NCT01690598. 
Study end points 
The primary endpoints of the phase I study were maximum tolerated dose (MTD) of veliparib, dose limiting 
toxicities (DLT), and identification of recommended dose for phase II. In the phase II study the primary 
endpoint was rate of response to combination treatment veliparib and topotecan in patients with relapsed 
advanced ovarian cancer without germline BRCA1/2 mutations or unknown BRCA1/2 status. Secondary 
endpoints were progression free survival (PFS), overall survival (OS), safety and toxicity.  
Evaluation and safety    
Assessment of tumor size and activity was performed at baseline and every three cycles (or prematurely if 
investigator suspected progression) by the RECIST 1.1 and GCIG CA-125 criteria. CT scans of 22 out of 27 
included subjects were available for evaluation by RECIST 1.1 criteria, however CT scans of six of those 
subjects were evaluated by RECIST 1.0 criteria. Baseline evaluation comprised a full clinical exam including 
gynecological examination and laboratory tests of liver, renal, bone marrow function and coagulation 
parameters. Laboratory tests were additionally run before every administration of topotecan. Toxicity was 
registered at baseline and before every treatment cycle. All adverse events were evaluated on the basis of 
the criteria for adverse events established by the NCI (National Cancer Institute) CT-CAE (Common 
terminology Criteria for Adverse Events) version 4.0 and if necessary reported to the relevant authorities 
according to the applicable rules.  
 
Results 
Twenty nine patients were screened and 27 found eligible and enrolled in the study. They all received at 
least one cycle of veliparib and topotecan treatment. Baseline characteristics are presented in Table 1. The 
majority of the patients had serous adenocarcinoma (88.9%) and approximately half of them (51.9%) were 
heavily pretreated with four or more previous lines of treatment (median 4; range [2-8]). CA-125 was 
generally highly elevated with a median of 504 [range 16-21.575]. The superiority of patients were 
platinum resistant (92.6%); two (7.4 %) were partially platinum sensitive.  
At inclusion, 26 of 27 patients were tested negative of a BRCA1/2 germline mutation; one patient was 
enrolled as “unknown BRCA1/2 status” and received one treatment cycle while BRCA1/2 testing was 
ongoing. The test result showed a pathogenic germline mutation in the BRCA1 gene, and the patient was 
subsequently excluded from further treatment according to the protocol. This subject was included in our 
intention-to-treat analysis.  
Of the 27 patients, 22 had primary ovarian cancer (81.5%), three had primary fallopian tube cancer (11.1 
%), and two had primary peritoneal cancer (7.4%). We enrolled 12 patients in the phase I part and another 
15 patients in the phase II part of the study. All of them initially received the starting dose of veliparib of 30 
mg twice daily; one patient (06) was dose reduced from cycle 2 onwards due to febrile neutropenia 
(veliparib 20 mg twice daily; topotecan 2 mg/m2). Consequently, topotecan was reduced to 2 mg/m2 from 
included individual number 07 due to dose limiting toxicity, and according to the protocol this was 
incompatible with dose escalation of veliparib. Therefore, moving into phase II, the initial starting dose of 
veliparib 30 mg twice daily continued as the starting dose for all patients.  
Treatment delay for more than seven days occurred in four of 27 patients; of those, 1 patient (01) was 
excluded from the study, since treatment was delayed for more than 28 days (due to ileus/volvolus). The 
other three patients had treatment delayed due to hematologic toxicity, none of those received G-CSF, and 
only one patient had a subsequent dose reduction of veliparib and topotecan.  
The median number of treatment cycles was three, range [1-12]. Four patients were excluded from the 
study before radiologic or serologic progression was established. Of those, two patients received one 
treatment cycle (exclusion due to a pathogenic BRCA1 mutation and long term treatment delay, 
respectively). One patient died of the cancer disease after four treatment cycles, and one patient withdrew 
her consent after two treatment cycles. 
Response rates: Clinical benefit (all stable disease) was seen in 10 patients (37%) in terms of disease control 
(Table 2). Two patients showed response according to the GCIG CA-125 criteria, one of which, however, at 
the same time had progressive disease according to the RECIST criteria and therefore discontinued 
treatment. Fifteen patients had stable disease according to GCIG CA-125, eight of which showed 
progressive disease according to the RECIST criteria. One of these patients continued treatment until 
progressive disease was confirmed according to both GCIG CA-125 and the RECIST criteria, whereas the 
remaining seven discontinued study treatment. None of the patients showed complete or partial 
radiological response and thus the best response according to RECIST was no change. Out of eight patients 
with stable disease by radiology, one had GCIG CA-125 progression at the same time. This patient 
continued study treatment until progression by both the RECIST and GCIG CA-125 criteria i.e. continued 
study treatment beyond progression.  As the vast majority (92.6 %) of patients was platinum resistant, 
stratification by platinum sensitivity was not considered statistically meaningful. One out of the two 
patients, that were partially platinum sensitive, was the subject included as “BRCA negative/unknown” and 
subsequently identified as a BRCA1 germline mutation carrier, showed clinical benefit (no change by RECIST 
and not evaluable by CA-125 criteria). The other partially platinum sensitive subject showed PD clinically 
and according to GCIG CA-125 criteria after one series of study treatment, and was hence withdrawn from 
protocol treatment without further CT scans.   
Survival: Median progression free survival (time from first dose of veliparib/topotecan until progression) 
was 2.8 months (95% CI [2.6-3.6]), Figure 1. Median overall survival (time from first dose of 
veliparib/topotecan until death) was 7.1 months (95% CI [4.8-10.8]), Figure 2. 
Safety: Adverse events reported, regardless of relation to study treatment, were mainly grade 1 or 2 and 
are listed in Table 3. The most commonly reported ones were fatigue (48.1%) and abdominal pain (55.5%). 
Features of myelosuppression were anemia (81.5%), neutropenia (22.2%), (neutropenia grade 3-4: 11.1%) 
and thrombocytopenia (29.6%). Grade 3-4 infection occurred in 22.2% of the patients. Serious adverse 
events occurred in 12 of 27 patients (44.4%) (Table 3). One SAE (grade 3 thromboembolic event with 
pulmonary embolism and an arterial aortic embolism) may have been related to the study treatment, but 
was considered most likely due to the disseminated cancer. 
 
Discussion 
Few studies have evaluated the effect of PARP inhibitor treatment in sporadic ovarian cancer [6–8] , as the 
concept of synthetic lethality exploiting the deficiency in DNA repair inherently existing in BRCA1/2 
mutation carriers, rapidly occurred as a main mechanism of action of this group of agents rather than a 
simple sensitizer to chemotherapy.  
The present phase I/II clinical trial of PARP inhibitor veliparib in combination with topoisomerase I inhibitor 
topotecan in recurrent epithelial ovarian cancer without germline BRCA1/2 mutations or with unknown 
BRCA1/2 status verifies the clinical safety of the combination treatment. None of the patients showed 
radiological response to the treatment. However, determining the fraction of patients with disease control 
by either CA-125 response or stable disease (RECIST or GCIG CA-125 criteria), 10 in 27 patients (37%) 
showed response/disease control of any kind, regardless of the duration of response. This is lower than in 
other studies on PARP inhibition in ovarian cancer, presumably due, in part, to difference in study 
population and the exclusion of BRCA1/2 positive as well as platinum sensitive patients rendering this 
cohort in a poor prognostic setting. 
Gelmon et al. [8] reported data on olaparib monotherapy in patients with recurrent high grade serous or 
poorly differentiated ovarian carcinoma, BRCA1/2 mutated and wildtype. They found partial responders 
among BRCA1/2 mutated as well as wildtype cancers (41% and 24%, respectively) and total disease control 
fractions of 62% (BRCA1/2 mutated) and 76% (BRCA1/2 wildtype). Important features of their findings were 
higher response rates among BRCA1/2 mutated cancers and platinum-sensitive cancers (regardless of 
mutational status), and that all of the BRCA1/2 wildtype responders had high grade serous carcinoma. 
Ledermann et al. [6] reported similar findings on olaparib maintenance monotherapy versus placebo in 
platinum-sensitive serous ovarian cancer with a statistically significant increase in PFS in favor of olaparib. 
This was observed in both BRCA1/2 mutated and wildtype cancers, but to a higher degree in the first group.  
Likewise they detected a tendency towards better overall survival in the olaparib group, especially among 
the BRCA1/2 mutated cancers, but the overall survival benefit was statistically insignificant[24]. Oza et al. 
[7] conducted a study of 156 patients with recurrent platinum-sensitive, high grade ovarian cancer with up 
to three previous platinum-based chemotherapy regimens, who had been progression free for at least 6 
months before inclusion. They compared carboplatin and paclitaxel chemotherapy alone with the same 
chemotherapy regimen in combination with olaparib and subsequent olaparib maintenance therapy and 
found a significant increase in PFS with the combination therapy. They also looked at subgroup analyses by 
BRCA1/2 mutation status and found the highest gain among BRCA1/2 mutated patients. However, they did 
not, either, find an increase in overall survival for the total group or the BRCA1/2 mutated subgroup.  
As outlined above, BRCA1/2 wildtype ovarian cancer patients exhibited response to PARPi, albeit at a lower 
magnitude in comparison with germline BRCA1/2 mutation carriers. Mirza et al. [25] demonstrated efficacy 
of PARPi niraparib as maintenance therapy in platinum-sensitive, recurrent ovarian cancer compared to 
placebo. In addition to stratifying patients by germline BRCA1/2 status they did HR deficiency testing on 
DNA from archival tumor tissue, including somatic BRCA1/2 mutation test. They found a statistically 
significant better response to niraparib compared to placebo in all subgroups; germline BRCA1/2 carriers, 
HR-deficient cases, and the overall non-germline BRCA1/2 group, but to a greater extend among BRCA1/2 
mutation carriers – germline and somatic alike. Kummar et al. [21] also did HR deficiency testing as part of a 
large gene expression profile of multiple (211) genes involved in DNA damage response, on tumor derived 
DNA from ovarian cancer patients receiving either oral cyclophosphamide alone or in combination with 
veliparib. However, they did not report a statistically significant correlation between any of the DNA repair 
defects identified, including BRCA1/2 mutations, and response to PARPi veliparib and/or chemotherapy 
treatment. All together encouraging why there may be a rationale for PARPi treatment in a BRCA1/2 
negative population as in the current study. 
PARPi have several biologic mechanisms of action; firstly inhibition of the catalytic activity of PARP 
culminating in accumulation of unrepaired DNA single strand breaks, secondly PARP trapping, by which 
PARP enzyme is trapped on DNA complexes thus interfering with DNA replication[26,27]. The contribution 
of each mechanism to the clinical activity of PARPi is not fully understood, and the PARP trapping efficiency 
of veliparib has been argued less potent compared to other PARPi[27]. Despite variation in PARP trapping 
efficiency among different PARPi, veliparib has demonstrated equal anti-tumor activity in pre-clinical in-
vivo models[28], supporting that veliparib is not less efficient than other PARPi.   
In summary there seems to be a subgroup of patients gaining the highest benefit from PARPi, i.e. ovarian 
cancers harboring BRCA1/2 mutations, high grade serous histology, and platinum sensitive disease. The 
studies described are different in terms of design and combination of drugs, and comparison with our 
response rate directly is therefore dubious. However, all but one study [21] identified response to PARPi, 
also among BRCA1/2 wildtype patients. Our finding of a smaller clinical benefit compared to other studies is 
consistent with these trends, as we analyzed a group of heavily pretreated ovarian cancers whose 
likelihood of response to any kind of treatment was low. Also, with the studies referred above in mind, our 
inclusion criteria per se identified the group of patients that would benefit the least from PARP inhibition, 
as we included only platinum resistant or partially sensitive cancers, and on top of this the key inclusion 
criterion was negative or unknown BRCA1/2 status. Additionally, the dosing regimen of topotecan and the 
MTD of veliparib (30 mg. twice daily) were lower than in most other studies, possibly explaining, in part, 
lack of response to therapy. Unfortunately toxicity, presumably due to topotecan, prevented further dosing 
escalation of veliparib according to study protocol.   
We suspected that a subgroup of responders could be identified as HR deficient due to other mechanisms 
than germline BRCA1/2 mutations, i.e. somatic BRCA1/2 mutations, mutations in other genes related to the 
HR pathway or by epigenetic mechanisms such as hypermethylation of BRCA1 promotor region. However, 
we refrained from performing BRCAness analyses on tumor tissue as best clinical response was disease 
control and translational research of good and poor responders, respectively, would be obsolete.  
Our hypothesis of PARPi acting as a chemosensitizer regardless of BRCA status was not verified in this small 
subset of ovarian cancer patients with limited clinical benefit. 
The adverse events in our study were similar to the ones reported in previous studies of combined PARP 
inhibitor and cytostatic treatment in ovarian cancers, and in other solid tumor types as well[21,29–32]. In 
general, toxicity was acceptable and manageable. The rates of adverse events were somewhat differing, 
probably due to divergent dosing regimens and distinct tumor types.  
 
Conclusion 
In conclusion, the safety of this combination regimen of veliparib and topotecan for recurrent epithelial 
ovarian cancer in non-BRCA1/2 germline mutation carriers was satisfying and comparable to findings in 
other studies. However, the best clinical response was stable disease.  There seems to be a subgroup of 
patients beyond the BRCA1/2 germline mutated cancers, which will benefit from treatment with PARPi. 
This group is yet to be specifically identified and future studies of PARP inhibitors with or without 
accompanying chemotherapy in sporadic ovarian cancer should have priority.  
Clinical Practice Points  
 Veliparib and topotecan is a safe combination treatment for recurrent epithelial ovarian cancer in 
non-BRCA1/2 germline mutation carriers. 
 In this study, best clinical response to the regimen was stable disease. 
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Table 1) Patient clinicopathologic characteristics (ECOG: Eastern Cooperative Oncology Group). 
 
Characteristic Value 
Age - years 
        Median   
        Range 
 
56.0 
35.8-73.5 
Histological tumour type – no. (%) 
        Serous adenocarcinoma 
                  HGSOC 
                  LGSOC 
                  Not graded/unknown 
        Non-serous 
                  Endometrioid adenocarcinoma 
                  Clear cell carcinoma 
 
 
24 (88.9) 
      17  (63.0) 
        1    (3.7) 
        6  (22.2)   
  3  (11.1) 
        1     (3.7) 
        2     (7.4) 
ECOG performance status – no. (%) 
         0 
         1 
         2 
 
17 (63.0) 
  9 (33.3) 
  1   (3.7) 
Number of previous treatment regimens – no. (%) 
         1 
         2 
         3 
         ≥4 
       
 
  0 
  7 (25.9) 
  6 (22.2) 
14 (51.9) 
Baseline CA-125 (kU/L) 
         Median 
         Range  
 
504 
16-21575 
Platinum sensitivity 
         Partially sensitive 
         Resistant 
 
  2   (7.4)  
25 (92.6) 
 
 
Table 2) Clinical responses in study patients for whom the response could be evaluated. 
 
              GCIG CA-125 
                           N=27 
RECIST 
N = 27 
PR (RE)  
n 
SD 
n 
PD 
n 
NE 
n  
Total 
n 
Disease Control  
n (%) 
CR                               n 0 0 0 0 0 0 
PR (RE)                       n 0 0 0 0 0 0 
SD                               n 1 5 1 2 9 8 
PD                               n 1 8 4 0 13 0 
NE                               n 0 2 2 1 5 2 
Total                          n 2 15 7 3 27 - 
Disease control n (%) 1 7 0 2 - 10 (37.0) 
 
 
Table 3) Adverse events of grade 1-2 reported in > 5 % of patients; adverse events grade 3-4 reported in 
any number of patients; total number of patients = 27. 
 
Adverse event Grade 1-2 – no.(%) Grade 3-4 – no. (%) 
Fatigue 13 (48.1) 2 (7.4)¤ 
Dizziness  7 (25.9) 0 
Alopecia  7 (25.9) 0 
Stomatitis  2   (7.4) 0 
Anorexia  9 (33.3) 1 (3.7)§ 
Nausea  8 (29.6) 2 (7.4) 
Vomiting  7 (25.9) 1 (3.7) 
Diarrhea  8 (29.6) 0 
Constipation  5 (18.5) 1 (3.7) 
Neuropathy – sensory  6 (22.2) 0 
Seizure  4 (14.8) 0 
Skin toxicity  2  (7.4) 0 
Edema  8 (29.6) 0 
Febrile neutropenia 1 (3.7) 1 (3.7) 
Fever without neutropenia  5 (18.5) 0 
Infection  3 (11.1) 6 (22.2) 
Anaemia 22 (81.5) 0 
Neutropenia  6 (22.2) 3 (11.1) 
Trombocytopenia  8 (29.6) 0 
Hypomagnesaemia 11 (40.7) 0 
Hypocalcaemia  3 (11.1) 0 
Abdominal pain 15 (55.5) 2 (7.4) # 
Pain unspecified 7 (25.9) 1 (3.7) ^ 
Dyspnea 2 (7.4 ) 0 
 
¤ Both were grade 3 adverse events; one patient experienced worsening from grade 2 to 3, the other from grade 0 to 3. 
§Worsening from grade 1 to 3. 
# Both patients registered with grade 3 abdominal pain after treatment and grade 1 at baseline. 
^The patient registered a worsening of leg-pain from 1 at baseline to 3 after treatment. 
 
 
